Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CCR9 | P51686 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096233 | 0.79 | CCR2 (0.57) | CCR2MAPTCCR9 | |
| SCHEMBL4086022 | 0.77 | CCR2 (0.50) | CCR2MAPTCCR9PTGER4PTGDR | |
| SCHEMBL4097358 | 0.74 | CCR2 (0.44) | CCR2MAPTCCR9PTGESPTGER4 | |
| SCHEMBL4086732 | 0.72 | MAPT (0.55) | CCR2MAPTALDH1A1ATM | |
| SCHEMBL4086613 | 0.70 | MAPT (0.50) | MAPTALDH1A1ATMALOX5 | |
| SCHEMBL4091277 | 0.70 | CCR2 (0.47) | CCR2MAPTCCR9PTGES | |
| SCHEMBL4092463 | 0.69 | CCR2 (0.55) | CCR2MAPTCCR9PTGES | |
| SCHEMBL4097150 | 0.67 | PTGES (0.47) | CCR2MAPTALDH1A1PTGESALOX5 | |
| SCHEMBL4104997 | 0.67 | CCR2 (0.53) | CCR2MAPTCCR9PTGES | |
| SCHEMBL4097557 | 0.67 | CCR2 (0.47) | CCR2MAPTCCR9PTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | NPY5R, TH, PTGES | CCR2 1118/4885MAPT 54/4885ALDH1A1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.